Skip to main content
ABCL
NASDAQ Life Sciences

AbCellera Q3: Loss Narrows to $40.8M, $890M Liquidity After $200M Raise

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$12.542
Mkt Cap
$4.051B
52W Low
$2.745
52W High
$15.015
52W Position info
357% above low
Off High info
16% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ABCL has more than doubled off its 52-week low of $2.745.

Summary

AbCellera's Q3 loss narrowed to $40.8M from $57.1M on $10.6M of revenue, and the $200M August raise lifted available liquidity to about $890M. ABCL635's positive Phase 2 data now anchors the pipeline, while ABCL575 will not advance past Phase 1.


Key Events · Earnings and Guidance · ABCL

  • Q3 Loss Narrows on Lower Spend

    Revenue was $10.6M versus $9.0M a year ago, and net loss fell to $40.8M, or $(0.13) per share, from $57.1M, or $(0.19) per share, as R&D dropped to $43.5M from $55.0M and SG&A to $13.6M from $25.0M.

  • Liquidity Tops $890M After Raise

    Cash, equivalents and marketable securities totaled $764.4M at September 30, 2026, and with over $100M of non-dilutive government funding total available liquidity exceeds $890M following the $200M August offering.

  • ABCL635 Phase 2 Data Anchor Pipeline

    ABCL635 cut moderate-to-severe VMS frequency 83% versus 33% for placebo at week 4, with a 58% versus 12% severity reduction; late-stage development is expected in 2027, with expansion into breast and prostate cancer treatment-induced VMS.

  • ABCL575 Shelved After Phase 1

    The OX40 ligand program met all Phase 1 endpoints with a ~65-day half-life supporting extended dosing, but AbCellera does not plan to develop it past Phase 1.


Analysis · ABCL · Life Sciences

The quarter itself is an improvement, not a transformation: revenue rose to $10.6M from $9.0M while the net loss narrowed to $40.8M from $57.1M as R&D and SG&A spending came down. The balance sheet is the real story — $764.4M in cash and marketable securities at September 30 plus over $100M of non-dilutive government funding gives roughly $890M of available liquidity, enough to fund late-stage development of ABCL635 without returning to equity markets soon. ABCL635 is now the value driver: positive Phase 2 VMS data with an 83% reduction in moderate-to-severe symptom frequency versus 33% for placebo, and management expects to start late-stage development in 2027 plus expand into cancer-treatment-induced hot flashes. The offset is ABCL575: the Phase 1 met all endpoints but the company will not develop it past Phase 1, writing off a pipeline asset investors had been tracking.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABCL was trading at $12.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $2.75 to $15.02. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABCL - Latest Insights

ABCL
Nov 09, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $12.90
Real-time Price: $12.89 info
Change: -$0.0100 (-0.08%) info
Market Cap: $4.051B info
ABCL
Aug 13, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.97
Real-time Price: $12.89 info
Change: +$1.92 (+18%) info
Market Cap: $4.051B info
ABCL
Aug 13, 2026, 12:05 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $10.32
Real-time Price: $12.89 info
Change: +$2.57 (+25%) info
Market Cap: $4.051B info
ABCL
Aug 11, 2026, 4:59 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $9.32
Real-time Price: $12.89 info
Change: +$3.57 (+38%) info
Market Cap: $4.051B info
ABCL
Aug 11, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $9.76
Real-time Price: $12.89 info
Change: +$3.13 (+32%) info
Market Cap: $4.051B info